BioVie Inc. Warrant (BIVIW) Stock Price
BIVIWStock
$0.29
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta—
BIVIW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.91%
Price vs S&P 500 (4W)-34.74%
VGM Score60.86
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIVIWBioVie Inc. Warrant | — | — | B | $0.29 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About BioVie Inc. Warrant
BioVie Inc is a clinical-stage biopharmaceutical company developing drug therapies for chronic debilitating conditions including liver disease, neurological and neuro-degenerative disorders, and certain cancers. The company is advancing NE3107 through a Phase 3 clinical trial for mild to moderate Alzheimer's disease. BIV201 is being developed to address life-threatening complications of liver cirrhosis caused by hepatitis, non-alcoholic steatohepatitis, and alcoholism.